How to start an ACE inhibitor

A guideline for medical practitioners from EdREN, the website of the Renal Unit, Royal Infirmary of Edinburgh.

Jump to summary

ACE inhibitors (angiotensin converting enzyme inhibitors) have been shown to be particularly effective in protecting renal function of damaged kidneys, especially if there is significant proteinuria. They are more effective than other classes of hypotensive drug in the presence of proteinuria. This guidance also covers angiotensin receptor blockers (ARBs).

Most patients who are commencing therapy with an ACE inhibitor can do so safely within the community. Patients who are likely to require very close supervision include those with:

Before starting

You must know Urea, Creatinine, Potassium, Sodium values.

The major risks from ACE inhibitors are of hyperkalaemia and deterioration of renal function. The risks are greater in individuals with unsuspected renal artery stenosis.

 Risk factors for hyperkalaemia and renal impairment

Peripheral vascular disease indicates a high risk of renal artery stenosis: other evidence of cardiovascular disease presents a moderate risk
Diabetes mellitus - at risk of renal artery stenosis, and if there is renal impairment, they are particularly prone to hyperkalaemia
Old age
Pre-existing renal impairment

Which ACE inhibitor?

Captopril is the original agent but is short acting and has some additional side effects. Enalapril may be best administered twice daily. Many newer agents (eg. lisinopril, ramipril) can be given once daily, and may be less likely to cause first-dose hypotension. Benefits seem to be class effects, so choice of agent may be reasonably decided by convenience and cost. In general, the same considerations apply to therapy with angiotensin receptor blockers (ARBs).

Other drugs and diet

In patients with renal impairment, potassium-sparing diuretics and potassium supplements should usually be discontinued unless there is continuing hypokalaemia. If continued, monitoring for hyperkalaemia should be closer.

Witholding diuretics for 2-3 days before commencing therapy will reduce the risk of first-dose hypotension. This is not usually necessary in simple hypertension but may be relevant in heart failure or renal failure requiring loop diuretics.

Non-steroidal anti-inflammatory drugs should be avoided if possible during the initiation phase.

The effects of ACE inhibition on blood pressure are potentiated by restriction of salt intake and by diuretics.

First dose hypotension

Predominantly affects dehydrated patients (eg taking a large dose of diuretics).

Monitoring

As mentioned, the major risks are of hyperkalaemia and deterioration of renal function. Check effect on blood pressure at the same time as monitoring blood tests.

LOW RISK PATIENTS (see above) - check creatinine and potassium at about 7 days

MODERATE AND HIGH RISK PATIENTS (see above) - check at 4 and 10 days. Checks should also be sent after dose increases, and if diuretic doses are increased.

For creatinine, a rise of over 20% is generally considered to be significant, but NICE/SIGN guidelines allow up to 30% rise (more info). Smaller rises are common and are to be expected in many patients.

For potassium, we suggest the following:
  5 - 5.5 recheck in 7 days
  5.6 - 6.0 stop ACE inhibitor and check in 7 days
  6.1 - 6.5 stop ACE inhibitor and check immediately
  >6.5 stop ACE inhibitor and check urgently*

*seek hospital attention if these values are likely (or proved) to be real (eg non-haemolysed sample that reached the lab promptly)

For some patients, the value of ACE inhibitors is such that dietary restriction and acceptance of modest hyperkalaemia may be an acceptable course.

If ACE inhibitors are discontinued, please inform any relevant specialist physician.

Dose titration

Increases can be made every week according to response, if you monitor the effects that frequently. We generally recommend a blood pressure target, although in patients with proteinuria there may be additional benefit from 'full dose' ACE inhibition even if the target blood pressures are achieved at a lower dose. See blood pressure targets in renal disease.

Side effects

Hyperkalaemia and renal impairment were mentioned above.

Cough is the most frequent side effect and is characteristically dry and troublesome. Try without the ACE inhibitor; if the problem is resolved, move on to an angiotensin II receptor antagonist such as irbesartan, candesartan.

Alternative agents

Angiotensin II receptor blockers (ARBs) seem to share most of the benefits of ACE inhibitors on the kidneys and are an excellent alternative in case of ACE inhibitor-induced cough. However, like ACE inhibitors, they are prone to cause hyperkalaemia and impaired renal function.

The non-dihydropyridine calcium antagonists (diltiazem, verapamil) share some glomerular haemodynamic properties with ACE inhibitors and are a reasonable second line agent if ACE inhibitors cause unacceptable hyperkalaemia.

Spironolactone may have proteinuria-reducing properties, and a number of other agents are under investigation.

 

Summary

Low risk

High risk
Week 1 Check blood, start drug Check blood, start drug
Check blood and BP at 4 days
Week 2 Check blood and BP Check blood and BP at 10 days
Week 3 Increase dose if required Increase dose if required
Week 4 (Check blood when at full dose) Check blood if dose of ACEI or diuretics increased

 

Further information

Blood pressure targets in renal disease. Explaining the targets that we set and why, from the EdREN Handbook.

Management of chronic renal impairment Principles of management are described in this document from the EdRenINFO pages.

EdRenINFO contains information about kidney diseases for patients, doctors and all medical staff. The EdRenHANDBOOK contains information aimed primarily at hospital doctors about immediate management of renal problems.

 

Contact us at renal@ed.ac.uk if you would like to comment on the content of these pages. This page was updated Thursday, February 5, 2009. Its original author was Dr Paddy Gibson.

 

Up to top of page
To EdRenINFO
Back to EdREN home page